Listen
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for hospital use.
-
Clinical Benefit
| Substantial |
The actual benefit of Tasigna is substantial. |
Clinical Added Value
| major |
In accelerated phase CML, after resistance or intolerance to prior therapy including imatinib, Tasigna shares the IAB level I (major) granted to Sprycel by the French Transparency Committee on 14 March 2007. |
| important |
In chronic phase CML, after resistance or intolerance to prior therapy including imatinib, Tasigna shares the IAB level II (high) granted to Sprycel by the French Transparency Committee on 14 March 2007. |
Contact Us
Évaluation des médicaments
